GILD
NASDAQGilead Sciences Inc.
Price$129.00-1.14 (-0.88%)
01:30 PM07:45 PM
News · 26 weeks116+4%
2025-12-072026-05-31
Mix6690d
- Insider23(35%)
- Other24(36%)
- SEC Filings12(18%)
- Earnings3(5%)
- Analyst2(3%)
- M&A2(3%)
Latest news
25 items- PRGilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South AfricaGilead applauds the leadership of the Government of South Africa and the Global Fund for accelerating access to lenacapavir, a long-acting HIV prevention medication. This marks an important step toward expanding access to lenacapavir for communities most affected by HIV. "South Africa is at the heart of global efforts to end HIV. With the country's launch of lenacapavir, there is now an opportunity to rapidly accelerate progress," said Daniel O'Day, Chairman and Chief Executive Officer of Gilead Sciences. "Through partnerships with country leadership, the Global Fund, and the U.S. State Department via PEPFAR, Gilead is working to bring lenacapavir to the communities most in need, ahead of
- PRGILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINECompanies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T cell engager in autoimmune diseases Foster City, Calif. and Mechelen, Belgium; June 4, 2026, 22.15 CET – Gilead Sciences, Inc. (NASDAQ:GILD) and Lakefront Biotherapeutics NV ((Euronext &, NASDAQ:LKFT) today announced the successful completion of the previously announced acquisition of Ouro Medicines to advance T cell engager therapies for autoimmune diseases. The acquisition adds gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager, to Gilead's growing inflammation portfolio and will be the foundation of Lakefront's clinical development pipeline. Gamgertamig is designed to
- PRGilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline– Companies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T cell engager in autoimmune diseases – Gilead Sciences, Inc. (NASDAQ:GILD) and Lakefront Biotherapeutics NV ((Euronext &, NASDAQ:LKFT) today announced the successful completion of the previously announced acquisition of Ouro Medicines to advance T cell engager therapies for autoimmune diseases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604796427/en/ The acquisition adds gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager, to Gilead's growing inflammation portfolio and will be the foundation of Lakefro
- INSIDERChairman & CEO O'Day Daniel Patrick sold $1,971,847 worth of shares (15,000 units at $131.46) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 617,567 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- PRGilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)– IDEAL Evaluated Livdelzi in People Living with PBC with Elevated ALP Levels (1-1.67xULN) on or Intolerant to UDCA – – 52-Week Results Demonstrate High and Sustained ALP Normalization and Generally Well-Tolerated Safety Profile – – Findings Add to Growing Evidence Supporting ALP Normalization as an Achievable Treatment Goal in PBC – Gilead Sciences, Inc. (NASDAQ:GILD) today announced positive results from a Phase 3 study in people with primary biliary cholangitis (PBC), showing that treatment with Livdelzi® (seladelpar) led to significantly more patients achieving normalization of alkaline phosphatase (ALP), a key liver marker of disease progression, compared with placebo after 52 we
- PRPhase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)– ALP Is a Key Marker of Disease Activity in People Living With PBC, With Elevations Above Normal Associated with Increased Risk of Disease Progression – – Further Analyses of the Phase 3 ASSURE Study Demonstrate Sustained ALP Normalization and Show Exploratory Outcomes of Stable or Improved Liver Stiffness, Providing Supportive, Long-term Evidence – Gilead Sciences, Inc. (NASDAQ:GILD) today shared new results from a post hoc analysis showing that Livdelzi® (seladelpar) was associated with high and sustained rates of normalization of a key liver marker (ALP) in people living with primary biliary cholangitis (PBC). In an ongoing Phase 3 study, participants with elevated ALP levels (betwe
- FDAFDA Approval for HEPCLUDEX issued to GILEAD SCIENCES INCSubmission status for GILEAD SCIENCES INC's drug HEPCLUDEX (ORIG-1) with active ingredient BULEVIRTIDE-GMOD) has changed to 'Approval' on 05/22/2026. Application Category: BLA, Application Number: 761468, Application Classification:
- PRFDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)– Chronic HDV is considered the most severe form of viral hepatitis due to rapid disease progression towards liver failure and liver-related death – – Approval introduces the first FDA-approved therapy for this disease with limited treatment options and high unmet need – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Hepcludex® (bulevirtide-gmod) 8.5 mg for the treatment of adults living with chronic hepatitis delta virus (HDV) infection, making it the first and only approved treatment for HDV in the United States. The FDA granted accelerated approval to Hepcludex based on reductions in HDV RNA
- PRGilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors– Recommendation Based on ASCENT-03 Study, Demonstrating Highly Statistically Significant and Clinically Meaningful Progression-Free Survival Versus Chemotherapy in PD-(L)1 Inhibitor Ineligible Patients– – Positive Opinion Marks a Significant Step Towards Introducing a Crucial First-line Treatment Option for People Living with Metastatic Triple-Negative Breast Cancer in the EU – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorization of Trodelvy® (sacituzumab govitecan-hziy) as a monotherapy for the treatment of adult
- PRNew ASCO and EHA 2026 Data Demonstrate Gilead and Kite's Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology– ASCO Presentations on Trodelvy® in First-line Metastatic Triple-Negative Breast Cancer and Anito-cel in Relapsed or Refractory Multiple Myeloma Build Toward Potential Commercial Launches – – EHA Updates Include Durability of KITE-753, Kite's Enhanced DuoCore™ CAR T-cell Therapy – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that together with Kite, a Gilead company, it will present more than 25 abstracts, including six oral presentations, at the 2026 ASCO Annual Meeting (May 29 – June 2) and the 2026 EHA Congress (June 11 – 14). These presentations underscore the increasing diversity of Gilead's oncology portfolio and pipeline reflecting a growing body of evidence across both s
- FDAFDA Approval for BIKTARVY issued to GILEAD SCIENCES INCSubmission status for GILEAD SCIENCES INC's drug BIKTARVY (SUPPL-26) with active ingredient BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE has changed to 'Approval' on 05/21/2026. Application Category: NDA, Application Number: 210251, Application Classification: Manufacturing (CMC)
- FDAFDA Approval for BIKTARVY issued to GILEAD SCIENCES INCSubmission status for GILEAD SCIENCES INC's drug BIKTARVY (SUPPL-26) with active ingredient BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE has changed to 'Approval' on 05/21/2026. Application Category: NDA, Application Number: 210251, Application Classification: Labeling
- PRGilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio– Acquisition Builds on Gilead's Leadership in Oncology with Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform – Gilead Sciences, Inc. (NASDAQ:GILD) today announced the successful completion of its previously announced acquisition of Tubulis GmbH, a private Germany-based, clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs). The acquisition brings Gilead next-generation ADC assets and a platform designed to maximize patient benefit through more selective delivery of diverse payloads to tumors. Tubulis' technologies enable the development of unique ADCs with superior biophysical properties, capable of achieving robus
- PRGilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease- The disease remains a public health challenge with an estimated 50,000 to 90,000 new cases each year - Gilead Sciences, Inc. (NASDAQ:GILD) today announced a renewed five-year collaboration with the World Health Organization (WHO), committing funding, strategic support and product donations to accelerate progress toward eliminating visceral leishmaniasis (VL), also known as kala-azar. VL, the second deadliest parasitic disease after malaria, is a sandfly-borne illness that attacks internal organs and can be fatal if untreated. The expanded agreement aims to improve access to life-saving diagnostic services and treatment for some of the world's most vulnerable communities, with a sharpe
- SECGilead Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)
- ANALYSTGilead Sciences upgraded by Maxim Group with a new price targetMaxim Group upgraded Gilead Sciences from Hold to Buy and set a new price target of $165.00
- INSIDERChief Financial Officer Dickinson Andrew D sold $396,810 worth of shares (3,000 units at $132.27) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 173,191 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- INSIDERChief Comm & Corp Aff Officer Mercier Johanna exercised 25,000 shares at a strike of $66.64 and sold $3,676,199 worth of shares (28,000 units at $131.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 125,779 units (SEC Form 4)4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
- SECSEC Form 424B5 filed by Gilead Sciences Inc.424B5 - GILEAD SCIENCES, INC. (0000882095) (Filer)
- SECSEC Form 144 filed by Gilead Sciences Inc.144 - GILEAD SCIENCES, INC. (0000882095) (Subject)
- PRGilead Prices $3 Billion of Senior Unsecured NotesGilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $3 billion, in an underwritten, registered public offering, consisting of $500 million of 4.250% senior notes maturing in 2028, $1 billion of 4.400% senior notes maturing in 2029, $1 billion of 4.600% senior notes maturing in 2031 and $500 million of 4.900% senior notes maturing in 2034. The offering is expected to close on May 20, 2026, subject to customary closing conditions. Gilead intends to use the net proceeds from this offering for general corpor
- SECSEC Form FWP filed by Gilead Sciences Inc.FWP - GILEAD SCIENCES, INC. (0000882095) (Subject)
- SECSEC Form 424B5 filed by Gilead Sciences Inc.424B5 - GILEAD SCIENCES, INC. (0000882095) (Filer)
- PRGilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026- Late-Breaking Livdelzi (Seladelpar) Data Expand the Evidence Base in PBC, while Interim Data Show Durable, Consistent Results Across Key Markers - - Bulevirtide Data Strengthen Evidence of Efficacy and Safety Across Broad HDV Populations - - New Findings Highlight Progress Toward HCV Elimination and Improved HDV Risk Insight - Gilead Sciences, Inc. (NASDAQ:GILD) will present findings from 29 abstracts, including late-breaking presentations at the European Association for the Study of the Liver (EASL) Congress, May 27-30, 2026, Barcelona. These presentations advance understanding of primary biliary cholangitis (PBC) and viral hepatitis. In PBC, Gilead will present randomized and lo
- SECSEC Form 13F-HR filed by Gilead Sciences Inc.13F-HR - GILEAD SCIENCES, INC. (0000882095) (Filer)
GILD FAQ
8 questionsWhat does Gilead Sciences Inc. do?
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus...Where does GILD stock trade?
Gilead Sciences Inc. (GILD) is listed on NASDAQ.What sector and industry is GILD in?
Gilead Sciences Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Gilead Sciences Inc. go public?
Gilead Sciences Inc. (GILD) completed its IPO in 1992.Does GILD pay a dividend?
Yes. GILD's next ex-dividend date is 2026-06-15 with a declared cash dividend of $0.82 per share, payable 2026-06-29.What are analysts saying about GILD?
Gilead Sciences Inc. has had 8 recent analyst actions on file. The most recent action was from Maxim Group: Buy on 2026-05-20.What companies are similar to GILD?
Notable peers in the same industry include ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), PFE (Pfizer Inc.), BMY (Bristol-Myers Squibb Company). Compare GILD side-by-side with any of them on Quantisnow.How can I track GILD on Quantisnow?
Quantisnow aggregates Gilead Sciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GILD to receive live email and push alerts on every new disclosure.